{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:05:57Z","timestamp":1756339557321,"version":"3.44.0"},"reference-count":12,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Tizanidine, a muscle relaxant, exerts its mechanism as a centrally acting alpha-2 adrenergic receptor agonist and binds to imidazoline receptors. Bradycardia and hypotension are adverse effects associated with alpha-2 adrenergic receptor agonists. A man in his 50s with a medical history of hypertension and chronic back pain presented with chest pain and hypertension. Pertinent medication history included metoprolol tartrate, lisinopril, hydralazine, hydrochlorothiazide and tizanidine and was continued. Following medication administration, the patient was hypotensive. Further episodes occurred that correlated with tizanidine administration and were more pronounced with concomitant lisinopril administration. Tizanidine was discontinued, and the hypotensive episodes resolved. Profound hypotension caused by a tizanidine\u2013lisinopril drug interaction is rare but potentially life-threatening. This reaction scored a 4 on the Naranjo Adverse Drug Reaction Probability Scale and Drug Interaction Probability Scale. Providers should be aware of this potential adverse reaction from the combination of medications.<\/jats:p>","DOI":"10.1136\/bcr-2024-262982","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:05:19Z","timestamp":1739365519000},"page":"e262982","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Profound hypotension following concomitant administration of tizanidine and lisinopril"],"prefix":"10.1136","volume":"18","author":[{"given":"Kayla","family":"Setzer","sequence":"first","affiliation":[{"name":"Internal Medicine and Pediatrics, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Ferris State University School of Pharmacy, Big Rapids, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Mersfelder","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Ferris State University, Big Rapids, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kelly","sequence":"additional","affiliation":[{"name":"Internal Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"2025082710164485000_18.2.e262982.1","unstructured":"Tizanidine . Lexi-drugs. uptodate lexidrug. uptodate inc. Available: https:\/\/online.lexi.com [Accessed 25 Jun 2024]."},{"key":"2025082710164485000_18.2.e262982.2","unstructured":"Zanaflex (tizanidine). Zug, Switzerland Covis Pharma; 2020."},{"key":"2025082710164485000_18.2.e262982.3","doi-asserted-by":"crossref","unstructured":"Jewell R . XPharm: the comprehensive pharmacology reference. Tizanidine 2007;1\u20136. doi:10.1016\/8978-008055232-3.62773-4","DOI":"10.1016\/B978-008055232-3.62773-4"},{"key":"2025082710164485000_18.2.e262982.4","first-page":"S6","article-title":"Tizanidine: neuropharmacology and mechanism of action","volume":"44","author":"Coward","year":"1994","journal-title":"Neurology (ECronicon)"},{"key":"2025082710164485000_18.2.e262982.5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11906-023-01248-2","article-title":"ACE-Inhibitors in hypertension: A historical perspective and current insights","volume":"9","author":"Cutrell","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"2025082710164485000_18.2.e262982.6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.14.1411"},{"key":"2025082710164485000_18.2.e262982.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19148373","article-title":"Adverse Effects of Angiotensin-Converting Enzyme Inhibitors in Humans: A Systematic Review and Meta-Analysis of 378 Randomized Controlled Trials","volume":"19","author":"Na Takuathung","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025082710164485000_18.2.e262982.8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"2025082710164485000_18.2.e262982.9","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423"},{"key":"2025082710164485000_18.2.e262982.10","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E161"},{"key":"2025082710164485000_18.2.e262982.11","doi-asserted-by":"publisher","DOI":"10.1177\/088307380001501211"},{"key":"2025082710164485000_18.2.e262982.12","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090657"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-262982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:16:52Z","timestamp":1756315012000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-262982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,12]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bcr-2024-262982"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-262982","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}